Direct Left Ventricle to Great Cardiac Vein Retroperfusion: A Novel Alternative to Myocardial Revascularization
Background. As the number of patients with diffuse coronary artery disease continues to grow, there is renewed interest in alternative methods of perfusing the ischemic myocardium. We tested the feasibility of myocardial retroperfusion via a direct left ventricle-to-great cardiac vein (LV-GCV) conduit to support regional contractility in this setting.
Methods. LV-GCV flow was established using an extracorporeal circuit in 5 dogs. Left ventricle (LV) pressure, aortic pressure, regional myocardial segment length, and circuit blood flow were measured prior to left anterior descending coronary artery (LAD) ligation, following LAD ligation, and after LV-GCV circuit placement. To eliminate backward flow during diastole, an in-line flow regulator was placed. Regional myocardial function was quantified by pressure-segment length loop area divided by end-diastolic segment length (PSLA/EDSL).
Results. LAD ligation reduced PSLA/EDSL from 10.0 ± 1.2 mm Hg ´ mm to 1.6 ± 0.3 mm Hg ´ mm (P < .05). With LV-GCV retroperfusion, mean peak systolic flow was +152 ± 14 mL/min, mean peak diastolic flow was -39 ± 11 mL/min, and net mean flow was +36 ± 13 mL/min. Regional function recovered to ~39% of baseline (3.9 ± 0.4 mm Hg ´ mm, P < .05). Upon elimination of backflow, mean flow increased to +41 ± 12 mL/min and regional function recovered even further to ~47% of baseline (4.6 ± 0.7 mm Hg ´ mm, P < .05). Conclusions. A LV-GCV circuit can significantly restore regional function to the acutely ischemic myocardium. An inline valve that eliminates backward diastolic flow improves regional function even further. This approach may provide an effective therapy for diffuse coronary disease not amenable to traditional revascularization strategies.
Kar S, Drury JK, Hajduczki I, et al. 1991. Synchronized coronary venous retroperfusion for support and salvage of ischemic myocardium during elective and failed angioplasty. J Am Coll Cardiol 18:271-82.nFarcot JC, Berdeaux A, Giudicelli JF, Vilaine JP, Bourdarias JP. 1983. Diastolic synchronized retroperfusion versus reperfusion: effects on regional left ventricular function and myocardial blood flow during acute >coronary occlusion in dogs. Am J Cardiol 51:1414-21.nLazar HL, Treanor P, Rivers S, Bernard S, Shemin RJ. 1995. Combining percutaneous bypass with coronary retroperfusion limits myocardial necrosis. Ann Thorac Surg 59:373-8.nMartin JS, Byrne JG, Ghez OY, et al. 2000. LV-powered coronary sinus retroperfusion reduces infarct size in acutely ischemic pigs. Ann Thorac Surg 69:84-9.nMeerbaum S. 1986. Coronary venous retroperfusion delivery of treatment to ischemic myocardium. Herz 11:41-54.nO'Byrne GT, Nienaber CA, Miyazaki A, et al. 1991. Positron emission tomography demonstrates that coronary sinus retroperfusion can restore regional myocardial perfusion and preserve metabolism. J Am Coll Cardiol 18:257-70.nOesterle SN, Reifart N, Hauptmann E, Hayase M, Yeung AC. 2001. Percutaneous in situ coronary venous arterialization: report of the first human catheter-based coronary artery bypass. Circulation 103:2539-43.nSuehiro K, Shimizu J, Yi GH, et al. 2001. Direct coronary artery perfusion from the left ventricle [published correction appears in J Thorac Cardiovasc Surg 2001;121:1063]. J Thorac Cardiovasc Surg 121:307-15.nKowallik P, Schulz R, Guth BD, et al. 1991. Measurement of regional myocardial blood flow with multiple colored microspheres. Circulation 83:974-82.nGerber TC, Kantor B, Keelan PC, Hayes DL, Schwartz RS, Holmes DR. 2000. The coronary venous system: an alternate portal to thenmyocardium for diagnostic and therapeutic procedures in invasive cardiology. Curr Interv Cardiol Rep 2:27-37.nKeelan PC, Kantor B, Gerber TC, Holmes DR, Schwartz RS. 2000. Bypass without the surgeon: the coronary veins as arterial conduits. Curr Interv Cardiol Rep 2:11-9.nBerdeaux A, Farcot JC, Bourdarias JP, Barry M, Bardet J, Giudicelli JF. 1981. Effects of diastolic synchronized retroperfusion on regional coronary blood flow in experimental myocardial ischemia. Am J Cardiol 47:1033-40.nChang BL, Drury JK, Meerbaum S, Fishbein MC, Whiting JS, Corday E. 1987. Enhanced myocardial washout and retrograde blood delivery with synchronized retroperfusion during acute myocardial ischemia. J Am Coll Cardiol 9:1091-8.nCostantini C, Sampaolesi A, Serra CM, et al. 1991. Coronary venous retroperfusion support during high risk angioplasty in patients with unstable angina: preliminary experience. J Am Coll Cardiol 18:283-92.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).